Michael B. Atkins, MD
Professor, Department of Medicine, Harvard Medical School
Director, Cutaneous Oncology and Biologic Therapy Programs and Clinical Res, Beth Israel Deaconess Medical Center
Contact Info
Michael Atkins
Beth Israel Deaconess Medical Center
375 Longwood Ave
Boston, MA, 02215
Mailstop: MASCO 415
Phone: 617-632-9270
Fax: 617-632-9260
matkins@bidmc.harvard.edu
Administrative Assistant
Cutaneous Oncology and Biologic Therapy Programs and Clinical Res
Beth Israel Deaconess Medical Center
375 Longwood Ave.
Boston, MA, 02215
Phone: 617-632-9270
Fax: 617-632-9260
sgraham@caregroup.harvard.edu
Beth Israel Deaconess Medical Center
375 Longwood Ave
Boston, MA, 02215
Mailstop: MASCO 415
Phone: 617-632-9270
Fax: 617-632-9260
matkins@bidmc.harvard.edu
Assistant
Susan Graham-McLaughlinAdministrative Assistant
Cutaneous Oncology and Biologic Therapy Programs and Clinical Res
Beth Israel Deaconess Medical Center
375 Longwood Ave.
Boston, MA, 02215
Phone: 617-632-9270
Fax: 617-632-9260
sgraham@caregroup.harvard.edu
DF/HCC Program Affiliation
Kidney CancerCutaneous Oncology and Melanoma
DF/HCC Associations
Principal Investigator, Kidney Cancer SPORECo-Director, Skin Cancer SPORE
Research Abstract
Dr Atkins is Deputy Chief of the Division of Hematology/Oncology, Director of the Cancer Clinical Trials Office, Director of the Cutaneous Oncology Program, and Director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center’s Cancer Center. He is leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and also a Professor of Medicine at the Harvard Medical School. Dr. Atkins is also Director of the DF/HCC Kidney Cancer SPORE grant, co–principal investigator of the DF/HCC Skin Cancer SPORE and principal investigator of the BIDMC ECOG main institution grant. He serves on the advisory boards of the Melanoma Foundation of New England, the Melanoma Research Foundation Breakthrough Consortium and the Kidney Cancer Association. He is a founding member and long time co-leader of the Cytokine Working Group and is past president of the International Society for Biological Therapy of Cancer.Dr. Atkins’ is a translational investigator whose major research interests are immunotherapy of malignancy, with specific emphasis on the use of cytokines and understanding and overcoming cancer associated immune suppression, novel treatments of melanoma and renal cell carcinoma, predictive markers for response to biologic therapy, and anti-angiogenic and targeted therapies. He played a key role in the clinical development of IL-2 from the early Phase I trials to its eventual approval by the FDA for treatment of metastatic renal cell carcinoma and melanoma and is currently investigating the potential utility of CTLA4 and the PD1 pathway antibodies, mechanisms of enhancing sensitivity of melanoma to selective raf pathway inhibitors, mechanisms of RCC resistance to VEGF targeted therapies, and opportunities for selecting patients for particular treatments based on tumor and immune based parameters.
